In GSK’s first quarter with Luke Miels as CEO, the company’s flagship shingles vaccine Shingrix set a new quarterly sales ...

Add Yahoo as a preferred source to see more of our stories on Google. If you’re over age 50 or have a suppressed immune system, you may have heard your doctor recommend the shingles vaccine. But what ...

Shingrix is a recombinant zoster vaccine approved in 2017, offering over 90% protection for at least seven years. The first ...

British pharmaceutical company GSK Plc GSK on Wednesday reported first-quarter core earnings of $1.25 per share (46.5 pence), ...

While sales for most of GSK’s shots slumped as vaccine skepticism continues to climb in the U.S., Shingrix jumped 20% to ...

Strong first-quarter results under new GSK CEO Luke Miels on Wednesday failed to impress investors, who raised concerns ‌that ...

Routine vaccinations offered to adults may help protect against dementia, recent research has shown. A joint Italian-Canadian neuroscience review, which analysed more than 100 million people, revealed ...

GSK stock declined 3% despite beating Q1 earnings estimates. Analysts note legal provisions contributed half the beat.

Medical experts have called for a full national vaccination programme for adults, similar to what is available for children, and for the shingles vaccine to be made free for older people.